Jonathan Schneck, M.D. Ph.D. Principal Investigator
Dr. Jonathan Schneck is a world-renowned leader in the fields of cellular immunology and immunoengineering. As senior JHU faculty with appointments in Pathology, Medicine, Oncology, ICE and BME, Dr. Schneck has led multiple scientific and educational programs, including the largest NIAID funded basic immunology P01 awarded to JHMI and was course director of the JHSOM GTS-immunology for over two decades. He has received awards from the Multiple Myeloma Foundation, American Cancer Society, and National Multiple Sclerosis Society and recently funding from Sanofi, the Thalheimer foundation, and the Denis Troper-Susan Wojcicki foundation. Dr Schneck has published in high profile journals including Nature Medicine, Cell, JCI, Immunity and Advanced Materials. Dr. Schneck recently finished a 5 year term as an associate editor at the Journal of Clinical Investigation, JCI, where he continues on the editorial board.
Dr. Schneck’s portfolio includes 7 issued US patents and multiple foreign patents. He is a founder of NexImmune, a Gaithersburg-based Biotech JHU spinout, based on technology from his lab. In February of 2021 NexImmune had a successful IPO raising $126.5 million in funding. Dr. Schneck has also received SBIR, TEDCO, and MII (State of Maryland) translational awards. He is currently head of the NexImmune SAB and is also Director of the the Johns Hopkins Translational ImmunoEngineering Center (JH-TIE NCBIB), an NCBIB, National Center for Biomedical Imaging and Bioengineering funded by the NIH. As part of JH-TIE, he seeks to bridge the gaps between Immunology and Biomedical Engineering. His primary areas of interest are in development of platforms for regulation of immune responses. Specifically, he has developed novel approaches, including artificial Antigen Presenting Cells, aAPC, and artificial Lymph nodes, aLN, to advance cancer immunotherapy. Interests in the lab also extend to understanding basic mechanism of immune regulation and the role of metabolic modulators in altering T cell immune responses.
